Ventriculo-Peritoneal Segment Held Larger Share of US Hydrocephalus Shunts Market
According to our new research study on “US Hydrocephalus Shunts Market Forecast to 2030 – Country Analysis – by Product, Type, Age Group, End User, and Country,” the US Hydrocephalus Shunts market size is expected to reach US$ 146.24 million by 2030 from US$ 109.61 million in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030.
Based on the type, the US hydrocephalus shunts is segmented into ventriculoperitoneal, ventriculo-atrial, ventriculo-pleural, and lumbo-peritoneal. The ventriculoperitoneal segment held a larger market share in 2022 and the same segment is anticipated to register a higher CAGR during 2022-2030. A ventriculoperitoneal (VP) shunt reduces the pressure exerted on the brain by fluid accumulation by diverting CSF from the brain's ventricles into the peritoneal cavity, the slot in the abdomen near the digestive organs. Ventriculoperitoneal (VP) shunts are among the most used tools for treating hydrocephalus. The tip of a distal catheter is placed in a cavity near the loops of the intestine and bowel. The CSF shunted is reabsorbed into the bloodstream and is eventually eliminated through normal urination. Ventriculo-peritoneal (VP) shunt procedure usually takes 90 minutes, followed by 3–4 days of recovery. Patients are discharged within 7 days after the procedure.
To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00030116
According to a research paper published in the National Center for Biotechnology Information (NCBI), a VP shunt greatly impacts advanced neurosurgical patient care. VP shunt can be lifesaving for benign disorders. However, for malignant tumors, the results are usually poor; often, these patients die from other causalities that aren’t related to the shunt. The possibility of VP shunt-related complications in emergency departments is high, ranging from 2% to 20%. Additionally, ~5–10% of neonates and young children require shunt revision.
B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc, Natus Medical Inc, Anuncia Inc, Desu Medical are among the leading companies operating in the US hydrocephalus shunts market.
A surge in funding from public and private organizations to fuel the R&D of medical devices has benefited the hydrocephalus shunts market. Hydrocephalus Association is one of the private organizations in the US that funds the research for hydrocephalus. The association invests in research to improve therapeutic outcomes and prevent hydrocephalus incidences among people.
A few of the funds associated with hydrocephalus shunts are mentioned below:
Thus, an upsurge in funding for R&D and clinical trials associated with hydrocephalus shunts provides growth opportunities for the US hydrocephalus shunt market.
Contact Us
Contact Us: The Insight Partners
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.